Standards & Guidelines

About

Guidelines and recommendations are designed to guide physicians in making decisions in daily practice. They provide a condensed, graded summary of all available evidence at the time of writing, allowing clinicians to make evidence-based choices for their patients.

Videos

Play Icon
AHA 2021 Late-breaker Discussion: The Digital Care Transformation Study
Harriette Van Spall
AHA 21 Late-breaker Discussion: The CHIEF-HF Clinical Trial
Harriette Van Spall, John Spertus
AHA 2021: Late-breaking Science Video Collection
Anushka Patel, Stephen Nicholls, Jeffrey Weitz et al
View from the Thoraxcenter: TCT 21 Late-breaking Science Wrap Up
Joost Daemen, Nicolas M Van Mieghem
View from the Thoraxcenter: AHA 21 Late-breaking Science Preview
Joost Daemen, Nicolas M Van Mieghem
Association Between AID/FID with Incident CV Disease and Mortality
Benedikt Schrage
View from the Thoraxcenter: TCT 21 Late-breaking Science Preview
Joost Daemen, Nicolas M Van Mieghem
Andrew JS Coats, Shelley Zieroth, Javed Butler et al
Aktualisierungen der europäischen Leitlinien zur Herzinsuffizienz: Eine Peer-to-Peer-Diskussion über SGLT-2-Hemmer
Gerd Hasenfuss, Michael Böhm, Stefan Anker
Información actualizada sobre las directrices europeas sobre insuficiencia cardíaca Un debate entre homólogos sobre los inhibidores del SGLT-2
Antoni Bayés-Genís, Julio Núñez
European Heart Failure Guideline Updates: A Peer-to-Peer Discussion on SGLT-2 Inhibitors
Andrew JS Coats, Carolyn Lam
View from the Thoraxcenter: ESC 21 Late-breaking Science Wrap Up
Joost Daemen, Nicolas M Van Mieghem
2021 ESC Clinical Practice Recommendations on the use of SGLT-2 Inhibitors in Heart Failure: An Assessment of their Impact
Andrew JS Coats, Lars H Lund, Michele Senni et al
Introduction to CV Health Concerns Among LGBTQ+ Populations
Billy A Caceres, Carl Streed
ESC 2021: Late-breaking Science Video Collection
George D Dangas, Adrian P Banning, Davide Cao et al
A Changing Paradigm: Defining the Future Role of SGLT-2 Inhibitors
Andrew JS Coats, Biykem Bozkurt, Carolyn Lam
Masterclass on The Global Burden of CV Disease in Women
Birgit Vogel, Harriette Van Spall
ESC 2021 Discussion: The EMPEROR-Preserved Trial
Stefan Anker, Harriette Van Spall
View from the Thoraxcenter – What's Hot at ESC 2021
Joost Daemen, Nicolas M Van Mieghem
SGLT2i Updates 2021
Stefan Anker, Shelley Zieroth, Andrew JS Coats et al
Masterclass: Smashing the Glass Ceiling
Cindy Grines, Harriette Van Spall

Videos

Play Icon
AHA 2021 Late-breaker Discussion: The Digital Care Transformation Study
Harriette Van Spall
AHA 21 Late-breaker Discussion: The CHIEF-HF Clinical Trial
Harriette Van Spall, John Spertus
AHA 2021: Late-breaking Science Video Collection
Anushka Patel, Stephen Nicholls, Jeffrey Weitz et al
View from the Thoraxcenter: TCT 21 Late-breaking Science Wrap Up
Joost Daemen, Nicolas M Van Mieghem
View from the Thoraxcenter: AHA 21 Late-breaking Science Preview
Joost Daemen, Nicolas M Van Mieghem
Association Between AID/FID with Incident CV Disease and Mortality
Benedikt Schrage
View from the Thoraxcenter: TCT 21 Late-breaking Science Preview
Joost Daemen, Nicolas M Van Mieghem
Andrew JS Coats, Shelley Zieroth, Javed Butler et al
Aktualisierungen der europäischen Leitlinien zur Herzinsuffizienz: Eine Peer-to-Peer-Diskussion über SGLT-2-Hemmer
Gerd Hasenfuss, Michael Böhm, Stefan Anker
Información actualizada sobre las directrices europeas sobre insuficiencia cardíaca Un debate entre homólogos sobre los inhibidores del SGLT-2
Antoni Bayés-Genís, Julio Núñez
European Heart Failure Guideline Updates: A Peer-to-Peer Discussion on SGLT-2 Inhibitors
Andrew JS Coats, Carolyn Lam
View from the Thoraxcenter: ESC 21 Late-breaking Science Wrap Up
Joost Daemen, Nicolas M Van Mieghem
2021 ESC Clinical Practice Recommendations on the use of SGLT-2 Inhibitors in Heart Failure: An Assessment of their Impact
Andrew JS Coats, Lars H Lund, Michele Senni et al
Introduction to CV Health Concerns Among LGBTQ+ Populations
Billy A Caceres, Carl Streed
ESC 2021: Late-breaking Science Video Collection
George D Dangas, Adrian P Banning, Davide Cao et al
A Changing Paradigm: Defining the Future Role of SGLT-2 Inhibitors
Andrew JS Coats, Biykem Bozkurt, Carolyn Lam
Masterclass on The Global Burden of CV Disease in Women
Birgit Vogel, Harriette Van Spall
ESC 2021 Discussion: The EMPEROR-Preserved Trial
Stefan Anker, Harriette Van Spall
View from the Thoraxcenter – What's Hot at ESC 2021
Joost Daemen, Nicolas M Van Mieghem
SGLT2i Updates 2021
Stefan Anker, Shelley Zieroth, Andrew JS Coats et al
Masterclass: Smashing the Glass Ceiling
Cindy Grines, Harriette Van Spall
Masterclass: New Universal Definition and Classification of Heart Failure
Harriette Van Spall, Biykem Bozkurt
Wrap-up of AHA 2019: An analysis of the late-breaking trials
Nicolas M Van Mieghem, Joost Daemen

Related Articles

Articles

Global Public Health Burden of Heart Failure

Gianluigi Savarese, Lars H Lund,

Citation: Cardiac Failure Review 2017;3(1):7–11.

DOI:

https://doi.org/10.15420/cfr.2016:25:2
Foreword

Andrew JS Coats, Giuseppe Rosano,

Citation: Cardiac Failure Review 2017;3(1):5–6

DOI:

https://doi.org/10.15420/cfr.2017:3:1:5
What the General Practitioner Needs to Know About Their Chronic Heart…

Frans H Rutten, Joe Gallagher,

Citation: Cardiac Failure Review 2016;2(2):79–84

DOI:

https://doi.org/10.15420/cfr.2016:18:1
The Role of Ivabradine and Trimetazidine in the New ESC HF Guidelines

Ivan Milinkovic, Giuseppe Rosano, Yury Lopatin,

Citation: Cardiac Failure Review, 2016;2(2):123–9

DOI:

https://doi.org/10.15420/cfr.2016:13:1